Piera Capranzano retweetledi

Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? Read this State-of-the-Art review in #EHJ 👉 ow.ly/Ze0p50XqmPK
@RoccoMontone @ehj_ed

English
Piera Capranzano
212 posts

@PCapranzano
Cardiologist; PhD; Professor at University of Catania, Italy






























A thorough understanding of study designs, populations, treatments, results, and limitations of trials testing P2Y12 inhibitor monotherapy vs. DAPT or vs. aspirin is required to consider adopting this treatment in clinical practice. This review addresses the use of aspirin-free antiplatelet strategies among patients undergoing PCI without a concomitant indication for oral anticoagulation, providing an overview of clinical evidence, guideline indications, practical implications, ongoing issues, and future perspectives. academic.oup.com/eurheartj/adva…



